000			02317 a2200685 4500
005			20250516072723.0
264		0	_c20120302
008			201203s 0 0 eng d
022			_a0394-6320
024	7		_a10.1177/039463201102400418 _2doi
040			_aNLM _beng _cNLM
100	1		_aRatto, G B
245	0	0	_aNeo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study. _h[electronic resource]
260			_bInternational journal of immunopathology and pharmacology _c
300			_a1005-16 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aCarcinoma, Non-Small-Cell Lung _ximmunology
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aChi-Square Distribution
650	0	4	_aCisplatin _xadministration & dosage
650	0	4	_aDeoxycytidine _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aFeasibility Studies
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunotherapy _xadverse effects
650	0	4	_aInterleukin-2 _xadverse effects
650	0	4	_aItaly
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLeukapheresis
650	0	4	_aLeukocytes, Mononuclear _ximmunology
650	0	4	_aLung Neoplasms _ximmunology
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoadjuvant Therapy
650	0	4	_aNeoplasm Staging
650	0	4	_aPilot Projects
650	0	4	_aPneumonectomy
650	0	4	_aProportional Hazards Models
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aSurvival Rate
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aGemcitabine
700	1		_aCosta, R
700	1		_aMaineri, P
700	1		_aAlloisio, A
700	1		_aPiras, M T
700	1		_aD'Agostino, A
700	1		_aTripodi, G
700	1		_aRivabella, L
700	1		_aDozin, B
700	1		_aBruzzi, P
700	1		_aMelioli, G
773	0		_tInternational journal of immunopathology and pharmacology _gvol. 24 _gno. 4 _gp. 1005-16
856	4	0	_uhttps://doi.org/10.1177/039463201102400418 _zAvailable from publisher's website
999			_c21447366 _d21447366